Literature DB >> 14627846

Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride.

J Hirvonen1, S Aalto, V Lumme, K Någren, J Kajander, H Vilkman, N Hagelberg, V Oikonen, J Hietala.   

Abstract

11C-Raclopride is a widely used positron emission tomography (PET) tracer for measurement of striatal D2 dopamine receptor binding characteristics. Recently, 11C-raclopride has also been used for quantification of thalamic D2 receptor binding. We studied reproducibility and validity issues on the thalamic D2 binding measurements using healthy volunteer test-retest data and simulated data. Eight healthy male volunteers received 11C-raclopride as a bolus injection in a standard test-retest design using 3-dimensional PET. The displacement of thalamic 11C-raclopride binding by the D2 receptor antagonist haloperidol was studied in two female schizophrenic patients. With regards to reproducibility and reliability, thalamic 11C-raclopride binding could be described with a simplified reference tissue model resulting in binding potentials (BPs) between 0.38 and 0.66. In comparison, the model failed to describe 11C-raclopride binding consistently in temporal cortex due to low specific signal. Measurement of thalamic 11C-raclopride BP was reproducible with a test-retest variability of 7.6+/-6.2% and reliable with an intraclass correlation coefficient (ICC) of 0.87. Comparable ICCs were observed in caudate and putamen (0.84-0.96). With regard to validity, subchronic low dose haloperidol treatment reduced specific 11C-raclopride binding equally in putamen and thalamus but a higher dose induced clearly higher D2 receptor occupancy in putamen than in thalamus. Noise simulations indicated that this can partly be explained by an over-estimation of thalamic D2 receptor BP in noisy conditions (low signal, high occupancy). The D2 receptor BP in putamen was clearly more resistant to noise. We conclude that the reproducibility and reliability of thalamic 11C-raclopride BP is good and equal to, or only slightly less than, those observed in caudate or putamen. However, the signal-to-noise ratio for quantification may become too low especially in receptor occupancy-type studies, leading to an artefactual underestimation of measured D2 receptor occupancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627846     DOI: 10.1097/00006231-200312000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  22 in total

1.  Reliability of striatal [¹¹C]raclopride binding in smokers wearing transdermal nicotine patches.

Authors:  Karmen K Yoder; Daniel S Albrecht; David A Kareken; Lauren M Federici; Kevin M Perry; Elizabeth A Patton; Qi-Huang Zheng; Bruce H Mock; Sean J O'Connor; Christine M Herring
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-19       Impact factor: 9.236

2.  Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.

Authors:  Sargo Aalto; Anna Brück; Matti Laine; Kjell Någren; Juha O Rinne
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

3.  PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility.

Authors:  Fumihiko Yasuno; Sandra M Sanabria; Donald Burns; Richard J Hargreaves; Subroto Ghose; Masanori Ichise; Frederick T Chin; Cheryl L Morse; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2007-04       Impact factor: 2.562

4.  Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography.

Authors:  Kati Alakurtti; Sargo Aalto; Jarkko J Johansson; Kjell Någren; Terhi Tuokkola; Vesa Oikonen; Matti Laine; Juha O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2010-05-05       Impact factor: 6.200

5.  Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects.

Authors:  K Collste; A Forsberg; A Varrone; N Amini; S Aeinehband; I Yakushev; C Halldin; L Farde; S Cervenka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-22       Impact factor: 9.236

Review 6.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

7.  Long-term test-retest reliability of striatal and extrastriatal dopamine D2/3 receptor binding: study with [(11)C]raclopride and high-resolution PET.

Authors:  Kati Alakurtti; Jarkko J Johansson; Juho Joutsa; Matti Laine; Lars Bäckman; Lars Nyberg; Juha O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-08       Impact factor: 6.200

8.  High long-term test-retest reliability for extrastriatal 11C-raclopride binding in healthy older adults.

Authors:  Nina Karalija; Lars Jonassson; Jarkko Johansson; Goran Papenberg; Alireza Salami; Micael Andersson; Katrine Riklund; Lars Nyberg; Carl-Johan Boraxbekk
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-10       Impact factor: 6.200

9.  Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride.

Authors:  Fumitoshi Kodaka; Hiroshi Ito; Yasuyuki Kimura; Saori Fujie; Harumasa Takano; Hironobu Fujiwara; Takeshi Sasaki; Kazuhiko Nakayama; Christer Halldin; Lars Farde; Tetsuya Suhara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-14       Impact factor: 9.236

10.  Segmentation of striatal brain structures from high resolution PET images.

Authors:  Ricardo J P C Farinha; Ulla Ruotsalainen; Jussi Hirvonen; Lauri Tuominen; Jarmo Hietala; José M Fonseca; Jussi Tohka
Journal:  Int J Biomed Imaging       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.